603 related articles for article (PubMed ID: 7539697)
1. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.
Hatzelmann A; Tenor H; Schudt C
Br J Pharmacol; 1995 Feb; 114(4):821-31. PubMed ID: 7539697
[TBL] [Abstract][Full Text] [Related]
2. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
Souness JE; Maslen C; Webber S; Foster M; Raeburn D; Palfreyman MN; Ashton MJ; Karlsson JA
Br J Pharmacol; 1995 May; 115(1):39-46. PubMed ID: 7647982
[TBL] [Abstract][Full Text] [Related]
3. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects.
Tenor H; Hatzelmann A; Church MK; Schudt C; Shute JK
Br J Pharmacol; 1996 Aug; 118(7):1727-35. PubMed ID: 8842438
[TBL] [Abstract][Full Text] [Related]
4. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
Dent G; Giembycz MA; Evans PM; Rabe KF; Barnes PJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422
[TBL] [Abstract][Full Text] [Related]
5. Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors.
Ezeamuzie CI
Eur J Pharmacol; 2001 Apr; 417(1-2):11-8. PubMed ID: 11301054
[TBL] [Abstract][Full Text] [Related]
6. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
[TBL] [Abstract][Full Text] [Related]
7. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
8. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone.
Souness JE; Villamil ME; Scott LC; Tomkinson A; Giembycz MA; Raeburn D
Br J Pharmacol; 1994 Apr; 111(4):1081-8. PubMed ID: 8032594
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.
Pan X; Arauz E; Krzanowski JJ; Fitzpatrick DF; Polson JB
Biochem Pharmacol; 1994 Aug; 48(4):827-35. PubMed ID: 7521642
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.
Torphy TJ; Barnette MS; Hay DW; Underwood DC
Environ Health Perspect; 1994 Dec; 102 Suppl 10(Suppl 10):79-84. PubMed ID: 7705312
[TBL] [Abstract][Full Text] [Related]
11. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.
Schmidt DT; Watson N; Dent G; Rühlmann E; Branscheid D; Magnussen H; Rabe KF
Br J Pharmacol; 2000 Dec; 131(8):1607-18. PubMed ID: 11139438
[TBL] [Abstract][Full Text] [Related]
12. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.
Underwood DC; Kotzer CJ; Bochnowicz S; Osborn RR; Luttmann MA; Hay DW; Torphy TJ
J Pharmacol Exp Ther; 1994 Jul; 270(1):250-9. PubMed ID: 8035322
[TBL] [Abstract][Full Text] [Related]
13. Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function.
Weston MC; Anderson N; Peachell PT
Br J Pharmacol; 1997 May; 121(2):287-95. PubMed ID: 9154339
[TBL] [Abstract][Full Text] [Related]
14. Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme.
Silva PM; Alves AC; Serra MF; Pires AL; Silva JP; Barreto EO; Cordeiro RS; Jose PJ; Teixeira MM; Lagente V; Martins MA
Br J Pharmacol; 2001 Sep; 134(2):283-94. PubMed ID: 11564646
[TBL] [Abstract][Full Text] [Related]
15. Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase.
Souness JE; Scott LC
Biochem J; 1993 Apr; 291 ( Pt 2)(Pt 2):389-95. PubMed ID: 8387267
[TBL] [Abstract][Full Text] [Related]
16. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors.
Rabe KF; Tenor H; Dent G; Schudt C; Nakashima M; Magnussen H
Am J Physiol; 1994 May; 266(5 Pt 1):L536-43. PubMed ID: 7515580
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.
Bethke T; Meyer W; Schmitz W; Scholz H; Stein B; Thomas K; Wenzlaff H
Br J Pharmacol; 1992 Sep; 107(1):127-33. PubMed ID: 1384905
[TBL] [Abstract][Full Text] [Related]
18. Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim.
Cortijo J; Villagrasa V; Navarrete C; Sanz C; Berto L; Michel A; Bonnet PA; Morcillo EJ
Br J Pharmacol; 1996 Sep; 119(1):99-106. PubMed ID: 8872362
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro.
Alves AC; Pires AL; Cruz HN; Serra MF; Diaz BL; Cordeiro RS; Lagente V; Martins MA
Eur J Pharmacol; 1996 Sep; 312(1):89-96. PubMed ID: 8891583
[TBL] [Abstract][Full Text] [Related]
20. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
